Frederick Locke, MD

Articles

Future Perspectives in Large B-Cell Lymphoma

December 26th 2023

Fred Locke, MD shares his perspective on the future treatment paradigm in large B-cell lymphoma, emphasizing CAR-T cells, allogeneic strategies, bispecifics, toxicity management, and treatment sequencing.

Emerging Bispecifics in the Treatment Paradigm for R/R LBCL

December 26th 2023

Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).

Observations in Progression Post-CAR T for Lymphoma

December 19th 2023

A comprehensive overview of clinical and patient factors that impact disease progression beyond CAR T-cell therapy in lymphoma.

Lisocabtagene Maraleucel: A Review of TRANSCEND NHL 001 in R/R LBCL

December 19th 2023

Gain insights into treatment outcomes of CAR T, highlighting lisocabtagene maraleucel and the TRANSCEND NHL 001 study for R/R LBCL.

ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL

December 12th 2023

A dive into the latest results from the ZUMA-1 study, evaluating axicabtagene ciloleucel (axi-cel) in relapsed/refractory LBCL.

Approaches to Treatment Sequencing in LBCL

December 12th 2023

Expert perspective on treatment sequencing strategies for patients with LBCL.

CAR T: A Review of Clinical Data for Second Line Treatments of Large B-Cell Lymphoma

December 5th 2023

Dr. Locke reviews the latest data from ZUMA-7 and TRANSFORM studies, evaluating CAR T in the second line setting for R/R LBCL.

Exploring LBCL: Transplant Eligibility and Second Line Treatment Selection of Novel Agents

December 5th 2023

Fred Locke, MD, provides an overview of transplant eligibility for patients with large B-cell lymphoma, highlighting second line strategies with CAR T-cell therapy and bispecific antibodies.

Role of Bispecifics and Future Promising Treatments in DLBCL

August 11th 2022

Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.

The Future of DLBCL Treatment

August 11th 2022

A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.

Management and Work-up of Patients for Salvage Therapy

August 8th 2022

The panelists share their approach to the treatment and work-up of patients who require salvage therapy.

Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy

August 8th 2022

Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.

A Closer Look at CAR T-Cell Therapy Clinical Trial Design

July 28th 2022

Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.

Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL

July 28th 2022

Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.

Therapeutic Sequencing and Bridging in DLBCL

July 22nd 2022

Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.

Treating Patients Who Relapse or Progress on CAR T-Cell Therapy

July 22nd 2022

Drs Nowakowski and Gordon discuss treatment options after disease relapse on CAR T-cell therapy.

A Closer Look at the Potential Impact of Bispecific Antibodies on the DLBCL Treatment Landscape

July 18th 2022

Physicians speculate on the potential impact of bispecific antibodies on the treatment landscape of DLBCL.

Comparing Real-World Evidence With Data From Clinical Trials

July 18th 2022

The panelists discuss the importance of using real-world evidence in addition to data from clinical trials to inform decision-making.

Tafasitamab plus Lenalidomide as a Treatment in Patients With R/R DLBCL

July 7th 2022

Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.

Selecting Among Available Treatment Options for Patients With Relapsed/Refractory DLBCL

July 7th 2022

Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.